Arrowhead Reports Q2 Net Loss Amidst Strong Pipeline Progress, REDEMPLO® Approvals, and New Madrigal Licensing Deal

summarizeSummary

Arrowhead Pharmaceuticals reported a Q2 net loss, but highlighted robust pipeline advancements, multiple global regulatory approvals for REDEMPLO®, and a new licensing agreement with Madrigal Pharmaceuticals, all supported by a strong cash position from recent financings.

check_boxKey Events

• Q2 FY2026 Financial Results

  Reported a net loss of $(132.7) million for the three months ended March 31, 2026, a significant decrease from a net income of $370.4 million in the prior-year period, primarily due to lower collaboration revenue recognition.

• Strengthened Liquidity and Capital Raise

  Maintains a strong cash and investments position of approximately $1.78 billion as of March 31, 2026, following successful financing activities including $700 million in convertible notes, a $230 million public offering, and $46.8 million from an at-the-market (ATM) offering.

• REDEMPLO® Global Approvals and Breakthrough Designation

  Secured regulatory approvals for REDEMPLO® (plozasiran) in China, Canada, and Australia, received a positive CHMP opinion in Europe, and was granted FDA Breakthrough Therapy designation for severe hypertriglyceridemia.

• Pipeline Expansion and Positive Data

  Initiated Phase 1/2a clinical trials for ARO-DIMER-PA (dual-gene target for ASCVD) and ARO-MAPT (tauopathies), and reported encouraging interim Phase 1/2a data for obesity programs ARO-INHBE and ARO-ALK7.

auto_awesomeAnalysis

Arrowhead Pharmaceuticals reported a net loss for Q2 FY2026, primarily due to the timing of collaboration revenue recognition compared to a large upfront payment in the prior year. However, the company significantly strengthened its financial position with over $1.78 billion in cash and investments from recent financing activities, providing a substantial runway for operations. Key operational highlights include multiple global regulatory approvals for REDEMPLO®, a Breakthrough Therapy designation, and the initiation of new clinical trials. A new licensing agreement with Madrigal Pharmaceuticals further validates Arrowhead's pipeline assets. Investors should focus on the continued pipeline advancement and commercialization efforts, which are well-funded, rather than the temporary shift to a net loss.